Methods: Prospective cohort study with follow-up for 24 months. From a population of patients diagnosed with dermatitis, the response to pharmacotherapy recommended by consensus and guidelines were evaluated in the real life. Scoring Atopic Dermatitis (SCORAD), Dermatology Life Quality Index (DLQI) and a subjective scale (SS) were used during each clinical assessment.
Results: We select 233 patients with dermatitis from the TECCEMA cohort in a tropical region. One hundred and seventy eight finished the follow-up. Most recommendations from guidelines were applied in all patients and after 6 months, a significant reduction in the SCORAD, DLQI and SS was observed especially in the group with moderate dermatitis. Nevertheless, after 2 years, only 33% of patients had a SCORAD <15%, DLQI <5 and SS <80%.
Conclusions: Drug treatment recommended by the guidelines allows achieving a significant reduction in the severity of eczema and improved quality of life. However, most patients in tropical region do not get complete control of the disease. It is necessary to develop treatments taking into account the special conditions of the region.